MX2022011349A - Agonista del receptor de glp-1, composición farmacéutica que comprende el mismo, y método para preparar el mismo. - Google Patents
Agonista del receptor de glp-1, composición farmacéutica que comprende el mismo, y método para preparar el mismo.Info
- Publication number
- MX2022011349A MX2022011349A MX2022011349A MX2022011349A MX2022011349A MX 2022011349 A MX2022011349 A MX 2022011349A MX 2022011349 A MX2022011349 A MX 2022011349A MX 2022011349 A MX2022011349 A MX 2022011349A MX 2022011349 A MX2022011349 A MX 2022011349A
- Authority
- MX
- Mexico
- Prior art keywords
- same
- pharmaceutical composition
- glp
- receptor agonist
- preparing
- Prior art date
Links
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 102000018658 Myotonin-Protein Kinase Human genes 0.000 abstract 1
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
- B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
- B01J23/44—Palladium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Materials Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un novedoso compuesto útil como agente para el tratamiento o la profilaxis de diversas enfermedades metabólicas tales como obesidad o diabetes e hiperlipidemia, por medio de una excelente actividad agonista de GLP-1 y un excelente perfil de DMPK, a un isómero del mismo o a una sal farmacéuticamente aceptable del mismo, a una composición farmacéutica que comprende el compuesto, y a un método para preparar el compuesto.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200033477 | 2020-03-18 | ||
| PCT/KR2021/003287 WO2021187886A1 (ko) | 2020-03-18 | 2021-03-17 | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
| KR1020210034452A KR102563111B1 (ko) | 2020-03-18 | 2021-03-17 | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011349A true MX2022011349A (es) | 2022-11-10 |
Family
ID=77771773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011349A MX2022011349A (es) | 2020-03-18 | 2021-03-17 | Agonista del receptor de glp-1, composición farmacéutica que comprende el mismo, y método para preparar el mismo. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230203021A1 (es) |
| JP (1) | JP7556588B2 (es) |
| AU (1) | AU2021237185B2 (es) |
| BR (1) | BR112022018646A2 (es) |
| CA (1) | CA3171173A1 (es) |
| CL (1) | CL2022002466A1 (es) |
| CO (1) | CO2022014271A2 (es) |
| IL (1) | IL296336A (es) |
| JO (1) | JOP20220213A1 (es) |
| MX (1) | MX2022011349A (es) |
| PE (1) | PE20230175A1 (es) |
| TW (1) | TWI825398B (es) |
| WO (1) | WO2021187886A1 (es) |
| ZA (1) | ZA202210199B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI751585B (zh) | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| BR112022007627A2 (pt) | 2019-10-25 | 2022-07-12 | Gilead Sciences Inc | Compostos moduladores do glp-1r |
| CN116323599A (zh) | 2020-08-06 | 2023-06-23 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| EP4204415A1 (en) | 2020-08-28 | 2023-07-05 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| EP4304711A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| WO2022202864A1 (ja) | 2021-03-24 | 2022-09-29 | 塩野義製薬株式会社 | 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物 |
| US20240300928A1 (en) * | 2021-04-08 | 2024-09-12 | Lg Chem, Ltd. | Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same |
| US11858918B2 (en) | 2021-04-21 | 2024-01-02 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| TWI843104B (zh) | 2021-05-20 | 2024-05-21 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| WO2023038039A1 (ja) | 2021-09-08 | 2023-03-16 | 塩野義製薬株式会社 | 抗肥満作用の関与する疾患の予防及び治療用医薬 |
| CN118401519A (zh) | 2021-10-25 | 2024-07-26 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| KR20240135652A (ko) * | 2022-05-20 | 2024-09-11 | 쳉두 띠아오 지우홍 파마수티칼 팩토리 | 벤즈이미다졸 또는 아자벤즈이미다졸 화합물, 이의 제조 방법 및 그의 용도 |
| WO2024063140A1 (ja) * | 2022-09-22 | 2024-03-28 | 塩野義製薬株式会社 | Ｇｌｐ－１受容体アゴニスト作用を有する単環化合物 |
| WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| WO2024107781A1 (en) | 2022-11-16 | 2024-05-23 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103221404B (zh) * | 2010-05-13 | 2015-12-16 | 安姆根有限公司 | 可用作pde10抑制剂的不饱和氮杂环化合物 |
| MX365923B (es) * | 2011-12-12 | 2019-06-20 | Celgene Int Ii Sarl | Derivados de acido carboxilico que comprenden cuatro ciclos, que actuan como moduladores del receptor del peptido 1 similar al glucagon (glp-1) para terapia de enfermedades como la diabetes. |
| PL3555064T3 (pl) | 2016-12-16 | 2023-03-06 | Pfizer Inc. | Agoności receptora GLP-1 i ich zastosowania |
| CA3058182A1 (en) * | 2017-03-27 | 2018-10-04 | Cardurion Pharmaceuticals, Llc | Heterocyclic compound |
| WO2019239371A1 (en) * | 2018-06-15 | 2019-12-19 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| KR20210152513A (ko) | 2019-04-12 | 2021-12-15 | 치루 레고르 테라퓨틱스 인코포레이티드 | Glp-1r 작용제 및 이의 용도 |
| TWI751585B (zh) | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| BR112022007627A2 (pt) | 2019-10-25 | 2022-07-12 | Gilead Sciences Inc | Compostos moduladores do glp-1r |
| CN114761395A (zh) * | 2019-12-02 | 2022-07-15 | 现代药品株式会社 | Glp-1受体激动剂 |
| US20230165846A1 (en) | 2020-02-13 | 2023-06-01 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
-
2021
- 2021-03-17 TW TW110109865A patent/TWI825398B/zh active
- 2021-03-17 MX MX2022011349A patent/MX2022011349A/es unknown
- 2021-03-17 JO JOP/2022/0213A patent/JOP20220213A1/ar unknown
- 2021-03-17 JP JP2022556239A patent/JP7556588B2/ja active Active
- 2021-03-17 BR BR112022018646A patent/BR112022018646A2/pt unknown
- 2021-03-17 US US17/912,129 patent/US20230203021A1/en active Pending
- 2021-03-17 AU AU2021237185A patent/AU2021237185B2/en active Active
- 2021-03-17 WO PCT/KR2021/003287 patent/WO2021187886A1/ko active Application Filing
- 2021-03-17 IL IL296336A patent/IL296336A/en unknown
- 2021-03-17 PE PE2022001989A patent/PE20230175A1/es unknown
- 2021-03-17 CA CA3171173A patent/CA3171173A1/en active Pending
-
2022
- 2022-09-09 CL CL2022002466A patent/CL2022002466A1/es unknown
- 2022-09-14 ZA ZA2022/10199A patent/ZA202210199B/en unknown
- 2022-10-05 CO CONC2022/0014271A patent/CO2022014271A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022018646A2 (pt) | 2022-11-08 |
| PE20230175A1 (es) | 2023-02-01 |
| TWI825398B (zh) | 2023-12-11 |
| JP7556588B2 (ja) | 2024-09-26 |
| US20230203021A1 (en) | 2023-06-29 |
| ZA202210199B (en) | 2023-06-28 |
| CA3171173A1 (en) | 2021-09-23 |
| CO2022014271A2 (es) | 2022-10-21 |
| TW202200559A (zh) | 2022-01-01 |
| JP2023520181A (ja) | 2023-05-16 |
| CL2022002466A1 (es) | 2023-03-03 |
| AU2021237185B2 (en) | 2023-11-30 |
| JOP20220213A1 (ar) | 2023-01-30 |
| IL296336A (en) | 2022-11-01 |
| WO2021187886A1 (ko) | 2021-09-23 |
| AU2021237185A1 (en) | 2022-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022011349A (es) | Agonista del receptor de glp-1, composición farmacéutica que comprende el mismo, y método para preparar el mismo. | |
| MX2023006186A (es) | Derivado de benzimidazol y método de preparación del mismo y uso médico del mismo. | |
| MX2024003295A (es) | Compuesto agonista del receptor thrb y metodo de preparacion y uso del mismo. | |
| ZA202200519B (en) | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents | |
| ZA202007688B (en) | Pharmaceutical combination, composition, and combination formulation containing glucokinase activator and ppar receptor activator, and preparation methods, and uses thereof | |
| EA202092169A1 (ru) | ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ АМИНОПРОПИОНАТНЫХ СОЕДИНЕНИЙ В ЛЕЧЕНИИ ИНФЕКЦИИ SARS-CoV-2 | |
| NZ721645A (en) | Compounds for use as gpr120 agonists | |
| WO2014059232A3 (en) | Substituted spiropiperidinyl compounds useful as gpr120 agonists | |
| WO2009121939A3 (en) | C-aryl glycoside compounds for the treatment of diabetes and obesity | |
| MX2021010122A (es) | Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. | |
| EA033250B1 (ru) | Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет | |
| MX2009009445A (es) | Derivados novedosos de benzamida y proceso para la preparacion de los mismos. | |
| EP2077846A4 (en) | BENZOXAZEPINE COMPOUNDS, PREPARATION THEREOF AND USE THEREOF | |
| MY147756A (en) | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists | |
| CR20210600A (es) | Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa | |
| MX2022000945A (es) | Composicion para incrementar la expresion de pgc-1alfa. | |
| MX2023006504A (es) | Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo. | |
| MX2023000943A (es) | Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y metodos de uso de los mismos. | |
| MX2021003662A (es) | Derivado de aminonorbornano y metodo de fabricacion del mismo y uso del mismo. | |
| PH12019550154A1 (en) | Azetidine derivative | |
| MX2022006104A (es) | Composicion farmaceutica oral que comprende compuesto de carbamato y metodo de preparacion para la misma. | |
| MX2021009971A (es) | Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos. | |
| MY162554A (en) | Novel benzamide derivatives | |
| MX343165B (es) | Agonistas del receptor 5-ht4 para el tratamiento de demencia. | |
| JOP20190278A1 (ar) | مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية |